The disease burden of respiratory syncytial virus in Infants
The disease burden of respiratory syncytial virus in Infants
PURPOSE OF REVIEW: To describe the current global burden of respiratory syncytial virus (RSV) in infants and its implications for morbidity, health resources and economic costs. RECENT FINDINGS: New prophylactic therapies are on the horizon for RSV in the form of long-acting monoclonal antibodies suitable for healthy infants and maternal immunizations. SUMMARY: Despite being responsible for significant global infant morbidity and mortality, until recently there have been no effective therapeutics available for healthy infants to protect them from RSV. Several new drugs are likely to be available within the next few years which could help relieve a huge burden on healthcare systems over the coming winters.
bronchiolitis, monoclonal antibodies, respiratory syncytial virus
379-384
Munro, Alasdair P.S.
59dacf7d-5977-49c4-b562-b2c719c9dcf4
Martinón-Torres, Federico
15086218-e8ba-4dc1-ab24-ce12dd5f2d05
Drysdale, Simon B.
cdb5ed23-255a-46a9-86ef-db40b20569ae
Faust, Saul N.
f97df780-9f9b-418e-b349-7adf63e150c1
1 October 2023
Munro, Alasdair P.S.
59dacf7d-5977-49c4-b562-b2c719c9dcf4
Martinón-Torres, Federico
15086218-e8ba-4dc1-ab24-ce12dd5f2d05
Drysdale, Simon B.
cdb5ed23-255a-46a9-86ef-db40b20569ae
Faust, Saul N.
f97df780-9f9b-418e-b349-7adf63e150c1
Munro, Alasdair P.S., Martinón-Torres, Federico, Drysdale, Simon B. and Faust, Saul N.
(2023)
The disease burden of respiratory syncytial virus in Infants.
Current opinion in infectious diseases, 36 (5), .
(doi:10.1097/QCO.0000000000000952).
Abstract
PURPOSE OF REVIEW: To describe the current global burden of respiratory syncytial virus (RSV) in infants and its implications for morbidity, health resources and economic costs. RECENT FINDINGS: New prophylactic therapies are on the horizon for RSV in the form of long-acting monoclonal antibodies suitable for healthy infants and maternal immunizations. SUMMARY: Despite being responsible for significant global infant morbidity and mortality, until recently there have been no effective therapeutics available for healthy infants to protect them from RSV. Several new drugs are likely to be available within the next few years which could help relieve a huge burden on healthcare systems over the coming winters.
Text
the_disease_burden_of_respiratory_syncytial_virus.13
- Version of Record
More information
e-pub ahead of print date: 23 August 2023
Published date: 1 October 2023
Additional Information:
Funding Information:
A.P.S.M. and S.F. both have their salary in part funded by the NIHR Southampton Clinical Research Facility and Biomedical Research Centre. F.M.-T. has received support for the present work from the Instituto de Salud Carlos III (Proyecto de Investigación en Salud, Acción Estratégica en Salud) ‘Fondo de Investigación Sanitaria’ (FIS; PI070069/PI1000540/PI1601569/PI1901090) from “plan nacional de I+D+I”.
Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Keywords:
bronchiolitis, monoclonal antibodies, respiratory syncytial virus
Identifiers
Local EPrints ID: 483070
URI: http://eprints.soton.ac.uk/id/eprint/483070
ISSN: 1473-6527
PURE UUID: 3a99e856-f492-49eb-a1ac-99c719069ebe
Catalogue record
Date deposited: 20 Oct 2023 17:40
Last modified: 18 Mar 2024 03:04
Export record
Altmetrics
Contributors
Author:
Alasdair P.S. Munro
Author:
Federico Martinón-Torres
Author:
Simon B. Drysdale
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
